{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Metastatic&page=2", "query": { "condition": "Neoplasms, Metastatic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Metastatic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T22:48:11.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01519414", "title": "Tivantinib in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Tivantinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 78, "start_date": "2012-01-11", "completion_date": "2015-08-18", "has_results": true, "last_update_posted_date": "2018-09-12", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 20, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519414" }, { "nct_id": "NCT00917384", "title": "Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "ramucirumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2009-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 14, "location_summary": "Bakersfield, California • La Jolla, California • Redlands, California + 11 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00917384" }, { "nct_id": "NCT03328026", "title": "Combination Study of SV-BR-1-GM With Retifanlimab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasm", "Metastatic Breast Cancer", "Breast Cancer Metastatic" ], "interventions": [ { "name": "SV-BR-1-GM", "type": "BIOLOGICAL" }, { "name": "Low dose cyclophosphamide", "type": "DRUG" }, { "name": "Interferon Inoculation", "type": "DRUG" }, { "name": "retifanlimab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BriaCell Therapeutics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-03-16", "completion_date": "2026-03-24", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 14, "location_summary": "Newport Beach, California • Santa Rosa, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03328026" }, { "nct_id": "NCT05574478", "title": "Metastatic Breast Cancer-Specific Prognostic Tool", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Patients and Caregivers Qualitative Interview", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2022-09-20", "completion_date": "2024-02-28", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05574478" }, { "nct_id": "NCT01974752", "title": "Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic", "Uveal Melanoma" ], "interventions": [ { "name": "75mg selumetinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 152, "start_date": "2014-04", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-01-05", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01974752" }, { "nct_id": "NCT00003335", "title": "Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "54 Years", "sex": "ALL", "summary": "Up to 54 Years" }, "enrollment_count": 44, "start_date": "1998-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003335" }, { "nct_id": "NCT07716735", "title": "Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Kidney Carcinoma", "Advanced Renal Cell Carcinoma", "Hereditary Leiomyomatosis and Renal Cell Carcinoma", "Metastatic Kidney Carcinoma", "Metastatic Renal Cell Carcinoma", "Skin Leiomyoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Uterine Corpus Leiomyoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Skin Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-12-01", "completion_date": "2035-12-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07716735" }, { "nct_id": "NCT04408898", "title": "SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "ADP-A2M4 in combination with pembrolizumab.", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Adaptimmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2020-07-02", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 8, "location_summary": "Phoenix, Arizona • San Diego, California • Kansas City, Kansas + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04408898" }, { "nct_id": "NCT02872116", "title": "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2031, "start_date": "2016-10-12", "completion_date": "2024-06-06", "has_results": true, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 27, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02872116" }, { "nct_id": "NCT02919449", "title": "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MV-NIS", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vyriad, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-08-03", "completion_date": "2018-01-19", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-09-26T22:48:11.215Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02919449" } ] }